ArticleMicromachines2023
3D Bioprinting of an Endothelialized Liver Lobule-like Construct as a Tumor-Scale Drug Screening Platform.
Article in Micromachines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 25 citations in OpenAlex.
- Fabricating transplantable, vascularized, and cholangiogenic bioartificial livers via three-dimensional bioprinting: a promising therapeutic strategy for liver failure.Hepatobiliary surgery and nutrition · 2026Article
- Characterization of the Coating Layers Deposited onto Curved Surfaces Using a Novel Multi-Nozzle Extrusion Printer.Micromachines · 2025Article
- 3D bioprinting lobule-like hepatorganoids with induced vascularization for orthotopic implantation.Materials today. Bio · 2025Article
- The Promise and Challenges of Bioprinting in Tissue Engineering.Micromachines · 2024Article
- 3D Bioprinting in Cancer Modeling and Biomedicine: From Print Categories to Biological Applications.ACS omega · 2024Review
- The cutting-edge progress in bioprinting for biomedicine: principles, applications, and future perspectives.MedComm · 2024Review
- Advancement in Cancer Vasculogenesis Modeling through 3D Bioprinting Technology.Biomimetics (Basel, Switzerland) · 2024Review
- Xeno-Free 3D Bioprinted Liver Model for Hepatotoxicity Assessment.International journal of molecular sciences · 2024Article
- Advances in 3D bioprinting for regenerative medicine applications.Regenerative biomaterials · 2024Review
- Current Biomedical Applications of 3D-Printed Hydrogels.Gels (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
3D cell culture models replicating the complexity of cell-cell interactions and biomimetic extracellular matrix (ECM) are novel approaches for studying liver cancer, including in vitro drug screening or disease mechanism investigation. Although there have been advancements in the production of 3D liver cancer models to serve as drug screening platforms, recreating the structural architecture and tumor-scale microenvironment of native liver tumors remains a challenge. Here, using the dot extrusion printing (DEP) technology reported in our previous work, we fabricated an endothelialized liver lobule-like construct by printing hepatocyte-laden methacryloyl gelatin (GelMA) hydrogel microbeads and HUVEC-laden gelatin microbeads. DEP technology enables hydrogel microbeads to be produced with precise positioning and adjustable scale, facilitating the construction of liver lobule-like structures. The vascular network was achieved by sacrificing the gelatin microbeads at 37 °C to allow HUVEC proliferation on the surface of the hepatocyte layer. Finally, we used the endothelialized liver lobule-like constructs for anti-cancer drug (Sorafenib) screening, and stronger drug resistance results were obtained when compared to either mono-cultured constructs or hepatocyte spheroids alone. The 3D liver cancer models presented here successfully recreate liver lobule-like morphology, and may have the potential to serve as a liver tumor-scale drug screening platform.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.